AUPH - Aurinia Pharmaceuticals Inc.
6.30 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 6.31 |
| Open | 6.27 |
| Bid | 6.30 x 3200 |
| Ask | 6.31 x 1400 |
| Day's Range | 6.22 - 6.35 |
| 52 Week Range | 5.06 - 7.85 |
| Volume | 372,427 |
| Avg. Volume | 881,477 |
| Market Cap | 579.282M |
| Beta (3Y Monthly) | 0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Yahoo Finance Video•2 months ago
Big Pharma faces the Senate in drug price hearings
Yahoo Finance's Adam Shapiro, Julie Hyman, Jessica Smith, and Brian Sozzi discuss the Pharma executives testifying in the Senate drug price hearings.
- American City Business Journals•2 hours ago
Former MedImmune president Greenleaf tapped to lead Canadian biotech
Peter Greenleaf was most recently CEO of Baltimore-based Cerecor Inc., a rare disease therapy company that topped the BBJ's list of fastest-growing public companies last year.
- Business Wire•11 days ago
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors.
- Zacks•12 days ago
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Motley Fool•last monthAurinia Pharmaceuticals Inc (AUPH) Q4 2018 Earnings Conference Call Transcript
AUPH earnings call for the period ending December 31, 2018.
- Associated Press•last month
Aurinia: 4Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 17 cents per share. The biotechnology company posted revenue of $29,000 in the period, missing Street forecasts. Three analysts surveyed ...
- Business Wire•last month
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.
- ACCESSWIRE•last month
Aurinia Pharmaceuticals Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 19, 2019 at ...
- Business Wire•last month
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease.
- Zacks•last month
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
Aurinia Pharmaceuticals Inc. today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.
- InvestorPlace•2 months ago
After Patent News, Aurinia Pharmaceuticals Still Has More to Prove
Aurinia Pharmaceuticals (NASDAQ:AUPH) leapt close to 20% on Monday. AUPH stock took off after the announcement of a new patent for the application method of its lupus nephritis drug.Source: Shutterstock This gave AUPH stock some much-needed excitement. Shares have languished between $5 and $6.50 for most of the past year, as investors await key clinical trial readouts. Bulls hope this patent news may finally break the gridlock and allow the stock to reach its highest levels in several years. However, Aurinia still has more work to do. Why The Patent News MattersThere was an interesting reaction with Aurinia stock after the news came out. At first, the stock didn't jump too much -- opening up just a few percent. But throughout the day, shares traded steadily higher as investors further considered the consequences.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Clinical-Stage Biotech Stocks to Buy On the one hand, this is an important development for Aurinia. One of the lingering issues with Aurinia has been that the primary patents around its Voclosporin were initially set to expire in 2022.Normally, a biotech company has a much longer window to generate exclusive revenues from its products before generic competitors launch their own versions. Given that short window, bears have suggested that Aurinia would have issues profiting adequately when the drug comes to market.Aurinia had several options to deal with this issue. They already managed to use one regulatory pathway to get a five-year extension out of 2027. So that had reduced the investment risk substantially. Still, most clinical stage biotech companies have patent exclusivity much longer than eight years, so investors were right to price that in as a risk for AUPH stock.With this patent, Aurinia may have overcome this challenge. What Changed, And What Hasn'tOn Monday, Aurinia published a press release, stating:"Notably, the allowed claims cover a method of modifying the dose of voclosporin in patients with lupus nephritis (LN) based on patient specific pharmacodynamic parameters."The new patent on Voclosporin runs out through 2037, giving Aurinia excellent protection from generic competition.That said, reading carefully, we see that the patent covers modification of the dose of Voclosporin, not the actual drug itself. It's seemingly unclear if generics could still compete with Voclosporin as long as they use a different dosing method. And there's still another much bigger question to deal with first: Will the drug be approved? After all, a patent won't matter if the drug never makes it to market.The all-important Phase III trial is set to deliver results around the end of 2019. It's far from a given that Voclosporin will succeed and go on to obtain FDA approval. The company's previous trial ran into significant safety issues with patients dying during the study. Given the FDA's concerns on safety issues, investors should be careful about assuming approval before the definitive trial results come in.On top of that, in the previous trial, the company's lower dose version of the drug showed a stronger clinical effect than the higher dose version. Again, there is a plausible explanation for this: management suggests the higher dose version wasn't tolerated well in patients. Still, an inconsistent dose response is another caution flag for biotech trials.To summarize, while the patent news is a plus for AUPH stock, don't overlook the small matter that the drug still has to perform in its pivotal phase III trial and pick up FDA approval. AUPH Stock VerdictThe company does have a few other options beyond the key lupus trial. It is also testing Voclosporin for other conditions, such as dry eye. That program produced a mixed set of clinical results recently. It missed its key endpoint, but showed stronger efficacy than expected.It's unclear what exactly this will mean for the dry eye program going forward. In any case, phase III results are still a few years away. Additionally, there is much more competition in that market than there would be for lupus nephritis.So, despite the flurry of attention for dry eye that Aurinia proponents have shown, don't get distracted from the main event. The lupus results should be coming up within a year from now. Those results will determine whether or not AUPH stock delivers for its shareholders.Finally, I should note the unambiguously positive thing about Aurinia at this point: its strong fiscal position. As of the most recent quarter, it had $139 million in cash, and was burning ~$45 million annually. That gives it more than two years to keep advancing the clinical pipeline. * 7 IPOs to Get Excited for in 2019 On top of that, the company subsequently announced a $30 million stock offering, which will add a few more quarters worth of working cash to its already substantial treasury. While Aurinia's ultimate success is far from certain, they've got a respected management team and enough cash to give Voclosporin time to attempt to prove its potential.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post After Patent News, Aurinia Pharmaceuticals Still Has More to Prove appeared first on InvestorPlace.
- Business Wire•2 months ago
Aurinia Closes At-The-Market Facility
Aurinia Pharmaceuticals Inc. today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million....
- Motley Fool•2 months ago
Here's Why Aurinia Pharmaceuticals' Stock Jumped Today
It looks like an important patent that could protect its lead candidate is a done deal.
- Business Wire•2 months ago
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase III confirmatory AURORA study.
- Business Wire•2 months ago
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
- Motley Fool•3 months ago
Is Aurinia Pharmaceuticals a Buy?
The pharma company bounced around for much of 2018, but there's intriguing potential in the pipeline.
- GlobeNewswire•3 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•3 months ago
Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial
Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye ...
- Business Wire•3 months ago
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerated and there was no statistical difference between VOS and Restasis® for the primary endpoint as both drugs exhibited low drop discomfort scores.
- Business Wire•3 months ago
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES). Aurinia will host a conference call and webcast presentation at 8:00am ET on Tuesday, January 22, 2019.
- Zacks•3 months ago
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
- TheStreet.com•3 months ago
My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout
In Tuesday's fast-paced Lightning Round of Jim Cramer's "Mad Money" program on CNBC, Jim commented that Aurinia Pharmaceuticals Inc. was "a great speculative stock." Let's check out the charts to see what sort of potential AUPH may have in the months ahead. In this daily bar chart of AUPH, below, we can see that prices broke out on the upside from a year-long sideways consolidation pattern.
- ACCESSWIRE•4 months ago
4 Pharma Stocks Getting a Boost on Thursday (12/20/18)
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.
- Business Wire•4 months ago
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P.
